Teva discontinues Phase 2 TOPAS-MSA study of emrusolmin after futility analysis

What happened: TevaDealroom has a profile for this one. Try Dealroom → announced on 2 November 2026 that it will discontinue the Phase 2 TOPAS-MSA study of emrusolmin (TEV-286) in adults with multiple system atrophy (MSA), a rare neurological disorder in which nerve cells progressively degenerate, impairing movement, balance and automatic body functions. The decision followed a prespecified interim futility analysis, which concluded the study was unlikely to meet its primary efficacy endpoint if continued. No safety concerns were identified, and Teva will assess available open-label extension data before deciding next steps.

Why it matters: MSA currently has no disease-modifying treatment. Emrusolmin, developed in partnership with German biotech MODAG GmbHDealroom has a profile for this one. Try Dealroom →, was designed to target the build-up of alpha-synuclein, a protein that clumps in the brain in MSA and Parkinson's disease. The halt adds to a mixed record for this class of drug and is a setback for Teva's push into innovative neuroscience beyond its generics business.

Read more: Teva, 2 November 2026 · Reuters, 2 November 2026